Introduction: While numerous studies relating to the lives of intellectually challenged people have been published previously, most have been from the caregiver's perspective and lack an insider's view. In addition, none of them were conducted in a Chinese context. Our purpose is to fill this gap by studying the life of Sue Leung, an intellectually disabled Chinese woman in Hong Kong.
Methods: Using a narrative approach that combined interviews and observational data collected over an extended time period, the research sought a holistic understanding of her life, how she interacts with others and the challenges and difficulties she faces.
Results: Sue Leung's life proved to be complex with social, spiritual, psychological, sexual and financial dimensions. Her story, in which she herself and other mentally impaired people are the actors, reflects to some degree the world of mentally impaired people, at least in Hong Kong. Their world is just as complex as that of anyone else. Violence, dangers, romances, friendships and goodwill also exist in that world.
Discussion: Sue Leung's story has helped to unravel the various dimensions of her life and enabled a deeper understanding of the challenges and difficulties a mildly intellectually disabled woman has to face in her life in Hong Kong. Social implications are discussed, and recommendations are made for future research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/appy.12121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Mod Pathol
October 2022
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Article Synopsis
- Ki67 is a key biomarker in breast cancer but struggles with consistent measurement between labs, prompting research into automated digital image analysis (DIA).
- The study assessed Ki67 levels using specially prepared slides from 30 breast cancer patients, with analysis conducted by 17 labs to evaluate consistency in scoring.
- Results showed a strong correlation between consecutive sections, but core biopsy samples had notably higher Ki67 scores than whole sections, indicating that core biopsies may provide a more accurate biological status of the tumor.
Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 in Breast Cancer Working Group (IKWG) consensus meeting, held in October 2019, assessed the current evidence for Ki67 IHC analytical validity and clinical utility in breast cancer, including the series of scoring studies the IKWG conducted on centrally stained tissues. Consensus observations and recommendations are: 1) as for estrogen receptor and HER2 testing, preanalytical handling considerations are critical; 2) a standardized visual scoring method has been established and is recommended for adoption; 3) participation in and evaluation of quality assurance and quality control programs is recommended to maintain analytical validity; and 4) the IKWG accepted that Ki67 IHC as a prognostic marker in breast cancer has clinical validity but concluded that clinical utility is evident only for prognosis estimation in anatomically favorable estrogen receptor-positive and HER2-negative patients to identify those who do not need adjuvant chemotherapy.
View Article and Find Full Text PDFAims: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The International Ki67 in Breast Cancer Working Group has undertaken a systematic programme to determine whether Ki67 measurement can be analytically validated and standardised among laboratories. This study addresses whether acceptable scoring reproducibility can be achieved on excision whole sections.
View Article and Find Full Text PDFAuthor Correction: The prognostic effects of somatic mutations in ER-positive breast cancer.
Nat Commun
November 2018
Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston 77030, TX, USA.
The original version of this Article contained errors in the depiction of confidence intervals in the NF1 BCSS data illustrated in Figure 3b. These have now been corrected in both the PDF and HTML versions of the Article. The incorrect version of Figure 3b is presented in the associated Author Correction.
View Article and Find Full Text PDFThe prognostic effects of somatic mutations in ER-positive breast cancer.
Nat Commun
September 2018
Lester and Sue Smith Breast Center and Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, 77030, TX, USA.
Here we report targeted sequencing of 83 genes using DNA from primary breast cancer samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal (MA12 trial) hormone receptor-positive (HR+) patients to determine interactions between somatic mutation and prognosis. Independent validation of prognostic interactions was achieved using data from the METABRIC study. Previously established associations between MAP3K1 and PIK3CA mutations with luminal A status/favorable prognosis and TP53 mutations with Luminal B/non-luminal tumors/poor prognosis were observed, validating the methodological approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!